Researchers at have identified an RNA molecule, known as a long noncoding RNA, that is responsible for controlling innate immune processes by making sure inflammatory genes in macrophages are switched off until needed. The study, “A Long Noncoding RNA lincRNA-EPS Acts as a Transcriptional Brake to Restrain…
Recent findings may help provide a new diagnostic indicator for the clinical detection of systemic lupus erythematosus (SLE) in previously undiagnosed patients. The study, “Evaluation of PBMC Distribution and TLR9 Expression in Patients with Systemic Lupus Erythematosus,” published in the Iranian Journal of Allergy, Asthma, and Immunology, revealed that specific…
Autoantibodies that naturally occur in the body of a population of patients with an ultra-rare type of autoimmune disorder called autoimmune polyendocrine syndrome type 1 (APS1 or APECED), could help fight a variety of human diseases including lupus.
Kadmon announced the publication of data from preclinical studies supporting its oral drug candidate, KD025, a small molecule ROCK2 inhibitor, as a potential treatment for autoimmune diseases such as systemic lupus erythematosus (SLE). The data indicated that KD025 worked to inhibit the rho-associated coiled-coil kinase 2 signaling pathway (ROCK2), reducing the development and function…
The Office of Minority Health has awarded the American College of Rheumatology’s (ACR) The Lupus Initiative (TLI) a one-year $335,000 grant to continue to expand its national education program by developing an expert-informed model specifically focused on improving health outcomes in lupus patients. “This model is the first of its kind to…
Novato-based Mount Tam Biotechnologies announced the U.S. Patent and Trademark Office has issued a key patent for the company’s lead systemic lupus erythematous (SLE) drug candidate, TAM-01, an innovative small-molecule modulator of the mTOR pathway that plays an important role in regulating the cell cycle. The patent, owned by The Buck Institute…
The Alliance for Lupus Research (ALR), the Lupus Research Institute (LRI) and the S.L.E. Lupus Foundation have merged to form the largest private sector organization dedicated to advance lupus research – The Lupus Research Alliance (LRA). With a new board of directors in place, the Lupus Research Alliance is geared…
A new assessment tool, called the lupus impact tracker or LIT, is valid and can be used by doctors in the clinic to track symptoms in systemic lupus erythematosus (SLE) and better discuss the disease with patients, researchers report. The study evaluating the tool, “Prospective Validation of the Lupus Impact Tracker:…
Non-Europeans more often carry genes increasing the likelihood of developing systemic lupus erythematosus (SLE), explaining the higher disease rates observed in people outside of Europe, according to a report by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s and St Thomas’ and King’s College London.
The Lupus Foundation of America (LFA) was awarded a one-year, $1 million grant from the Office of Minority Health at the Department of Health and Human Services (HHS) to develop an education program on clinical trials that educates and recruits minorities and the disadvantaged, especially groups that are underrepresented in clinical research.